Drug Profile


Alternative Names: Alna; Alna OCAS; Amsulosin; Expros; Flomax; Flomax MR; Harnal; Harnal D; Harnalidge D; Josir; Josir LP; Omic; Omix LP; Omnic; Omnic-OCAS; Pradif; Pradif T; Secotex; TOCAS; Urolosin; Urolosin OCAS; WOWTAB®; Y 617; YM 12617; YM 617

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Astellas Pharma
  • Developer Astellas Pharma; Boehringer Ingelheim; CSL
  • Class Small molecules; Sulfonamides
  • Mechanism of Action Alpha 1a adrenergic-receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Benign prostatic hyperplasia
  • Discontinued Neurogenic bladder; Prostatitis; Urinary calculi; Urination disorders

Most Recent Events

  • 30 Mar 2016 Launched for Benign prostatic hyperplasia in Taiwan (PO) before March 2016
  • 01 Aug 2014 Astellas completes a phase I drug interaction study in volunteers in Germany (NCT02169713)
  • 01 May 2014 Astellas Pharma initiates enrolment in a phase I drug interaction study in volunteers in Germany (NCT02169713)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top